CJC-1295 + Ipamorelin Blend (10 mg Vial) Dosage Protocol

CJC-1295 + Ipamorelin combines a GHRH analog (5 mg) with a selective GHRP (5 mg) in a single vial — pairing GH-releasing-hormone stimulation with growth-hormone-secretagogue amplification for synergistic pulsatile GH release.

Dosing & Reconstitution Guide

Route: Subcutaneous  |  Frequency: 1–3× daily  |  Half-life: ~30 minutes (CJC-1295 no-DAC); ~2 hours (ipamorelin)

Standard Approach (3 mL = 3.33 mg/mL)

Reconstituting with 3 mL bacteriostatic water produces a concentration of 3.33 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.

Reconstitution Steps

1. Wipe the vial stopper and BAC water vial with alcohol; let dry.
2. Draw 3 mL of bacteriostatic water into a sterile syringe.
3. Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
4. Gently swirl until fully dissolved. Do not shake.
5. Label with reconstitution date. Refrigerate at 2–8°C; use within 28 days.

Supplies Needed

Estimates for an 8-week and 12-week cycle at 400 mcg per dose, 1–3× daily (3 doses/week).

Protocol Overview

The CJC-1295 (no-DAC) + ipamorelin blend is one of the most-cited GH-axis research stacks. The two peptides work via complementary pituitary pathways — GHRH receptor activation (CJC-1295) plus ghrelin receptor activation (ipamorelin) — to produce GH pulses 5–10× larger than either component alone.

Cycle lengths are typically 12–16 weeks with 4-week breaks. Effects on body composition, sleep quality, and recovery accumulate gradually over 8–12 weeks.

Dosing Protocol

Titration schedule (per peptide; doses are combined CJC-1295 + Ipamorelin in equal parts):

• Weeks 1–2 (titration): 200 mcg per dose, 1–3× daily.
• Weeks 3–4: 300 mcg per dose, 1–3× daily.
• Weeks 5–6: 400 mcg per dose, 1–3× daily.
• Weeks 7–12 (target): 550 mcg per dose, 1–3× daily (pre-bed mandatory; AM/pre-workout optional).

Cycle structure: 12–16 weeks continuous, then 4-week break. Some users run 12 weeks on, 4 weeks off, repeat.

Timing: Pre-bed dose 30–60 min before sleep, fasted (no food/protein in last 2h). Pre-workout dose ~30 min before training, fasted.

Bloodwork cadence: IGF-1 every 8–12 weeks. Some users also monitor cortisol given ipamorelin's near-zero (but non-zero) cortisol effect.

Storage Instructions

Important Notes

How This Works

This blend pairs CJC-1295 without DAC (a GHRH analog) with ipamorelin (a selective GHRP / ghrelin mimetic). The two work through complementary pituitary pathways: CJC-1295 binds GHRH receptors on somatotrophs to trigger GH release; ipamorelin binds GHS-R receptors and amplifies the GHRH-driven pulse.

The combination produces larger GH pulses than either component alone, mimicking the body’s natural pulsatile pattern. Ipamorelin's selectivity (no significant cortisol or prolactin elevation) makes the blend cleaner than older GHRPs like GHRP-2 or GHRP-6.

Potential Benefits & Side Effects

Potential Benefits

• Synergistic GH pulse — larger than either component alone.
• Pulsatile pattern mimics physiological GH rhythm.
• Ipamorelin selectivity avoids cortisol/prolactin spikes.
• Often combined with pre-bed dosing for sleep-quality benefits.

Side Effect Profile

• Injection-site reactions.
• Mild head flushing post-dose.
• Transient hunger increase (ghrelin pathway).
• Mild fluid retention.

Lifestyle Factors

• Avoid eating for 30+ minutes after injection.
• Pre-bed timing aligns with natural overnight GH pulse.
• Resistance training amplifies outcomes.

Injection Technique

• Subcutaneous into abdomen, thigh, or upper arm.
• Rotate sites with each dose.
• 90° angle with short insulin needle.